PL362838A1 - Antagoniści somatostatyny - Google Patents

Antagoniści somatostatyny

Info

Publication number
PL362838A1
PL362838A1 PL02362838A PL36283802A PL362838A1 PL 362838 A1 PL362838 A1 PL 362838A1 PL 02362838 A PL02362838 A PL 02362838A PL 36283802 A PL36283802 A PL 36283802A PL 362838 A1 PL362838 A1 PL 362838A1
Authority
PL
Poland
Prior art keywords
somatostatin antagonists
somatostatin
antagonists
Prior art date
Application number
PL02362838A
Other languages
English (en)
Inventor
David H. Coy
William A. Murphy
Walajapet G. Rajeswaran
Original Assignee
The Administrators Of The Tulane Educational Fund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Administrators Of The Tulane Educational Fund filed Critical The Administrators Of The Tulane Educational Fund
Publication of PL362838A1 publication Critical patent/PL362838A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL02362838A 2001-03-08 2002-03-05 Antagoniści somatostatyny PL362838A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27430801P 2001-03-08 2001-03-08
PCT/US2002/006676 WO2002072602A2 (en) 2001-03-08 2002-03-05 Somatostatin antagonists

Publications (1)

Publication Number Publication Date
PL362838A1 true PL362838A1 (pl) 2004-11-02

Family

ID=23047655

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02362838A PL362838A1 (pl) 2001-03-08 2002-03-05 Antagoniści somatostatyny

Country Status (16)

Country Link
US (3) US7378488B2 (pl)
EP (1) EP1372688B1 (pl)
JP (3) JP4204322B2 (pl)
AR (1) AR035942A1 (pl)
AT (1) ATE394114T1 (pl)
AU (1) AU2002258465B2 (pl)
CA (1) CA2439498A1 (pl)
CZ (1) CZ299362B6 (pl)
DE (1) DE60226419D1 (pl)
DK (1) DK1372688T3 (pl)
ES (1) ES2306766T3 (pl)
HU (1) HUP0401535A3 (pl)
NO (1) NO20033911L (pl)
PL (1) PL362838A1 (pl)
RU (2) RU2328504C2 (pl)
WO (1) WO2002072602A2 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2425804A1 (en) * 2000-10-20 2002-04-25 The Administrators Of The Tulane Educational Fund Urotensin-ii agonists and antagonists
RU2328504C2 (ru) 2001-03-08 2008-07-10 Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд Антагонисты соматостатина
US7312304B2 (en) * 2001-04-09 2007-12-25 The Administrators Of The Tulane Educational Fund Somatostatin agonists
EP1522311A1 (fr) 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
US8017575B2 (en) * 2004-12-15 2011-09-13 Wilfred Wayne Lautt Treatment of insulin resistance by modulating somatostatin using somatostatin receptor antagonists
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
EP2076535B1 (en) 2006-10-16 2013-03-06 The Salk Institute For Biological Studies Receptor(sstr2)-selective somatostatin antagonists
EP2168983A1 (fr) 2008-09-30 2010-03-31 Ipsen Pharma Nouveaux composés octapeptidiques et leur utilisation thérapeutique
US9464306B2 (en) 2008-10-29 2016-10-11 Kaneka Corporation Method for producing L-amino acid
EP2399931A1 (fr) * 2010-06-22 2011-12-28 Ipsen Pharma S.A.S. Nouveaux composés octapeptidiques et leur utilisation thérapeutique
RU2740464C2 (ru) 2016-02-09 2021-01-14 СиДиАрДи ВЕНЧЕРЗ ИНК. Антагонисты рецепторов соматостатина и способы их применения
WO2021111503A1 (ja) * 2019-12-02 2021-06-10 花王株式会社 光吸収層及びその製造方法、分散液、光電変換素子、並びに太陽電池

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0098457B1 (en) * 1980-02-14 1987-08-05 Sandoz Ag (1s,2r,3r)- and (1r,2s,3s)-nitrilo-1-carbonyl-3-methyl-2-oxy-heptanes and -hept-5-enes useful in the total synthesis of cyclosporins and processes for their production
EP0278158A3 (en) 1986-11-12 1990-05-23 Merck & Co. Inc. Renin inhibitors containing phenylalanyl-histidine replacements
JPS63146850A (ja) 1986-11-12 1988-06-18 メルク　エンド　カムパニー　インコーポレーテツド フエニルアラニル−ヒスチジン代用成分を有するレニン阻害剤
EP0273696A2 (en) 1987-01-02 1988-07-06 Merck & Co. Inc. Renin inhibitors containing histidine replacements
CH679045A5 (pl) 1987-06-29 1991-12-13 Sandoz Ag
JPS6426599U (pl) 1987-08-10 1989-02-15
DE68928278T2 (de) 1988-02-10 1998-03-12 Tap Pharmaceuticals Inc Lhrh-analog
WO1991009056A1 (en) * 1989-12-08 1991-06-27 The Administrators Of The Tulane Educational Fund Octapeptide analogs of somatostatin having threonine at the sixth position
US7223833B1 (en) * 1991-05-24 2007-05-29 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
JPH06509075A (ja) 1991-07-01 1994-10-13 ユニヴァーシティ　テクノロジーズ　インターナショナル　インコーポレイテッド ＧｎＲＨ及び他の生物学的に活性なリガンドの非感度低下性類縁体
JP3480848B2 (ja) * 1992-06-19 2003-12-22 タカラバイオ株式会社 環状ペプチドの合成方法
US5569741A (en) * 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
SI0788509T1 (en) * 1993-08-09 2003-10-31 Societe De Conseils De Recherches Therapeutic peptide derivatives
GB9402767D0 (en) 1994-02-14 1994-04-06 Sandoz Ltd Improvements in or relating to organic compounds
US5696230A (en) * 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
US5750499A (en) * 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
US5846934A (en) * 1996-02-20 1998-12-08 American Cyanamid Company Pure somatostatin antagonist and methods of use thereof
US6355613B1 (en) * 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
WO1998008528A1 (en) 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
WO1998010786A2 (en) * 1996-09-12 1998-03-19 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
BR9714376A (pt) * 1996-12-04 2000-03-21 Sod Conseils Rech Applic Antagonistas de somatostatina
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
ES2345280T3 (es) 2001-03-06 2010-09-20 The Administrators Of The Tulane Educational Fund Procedimiento de modulacion de la proliferacion de celulas de carcinoma tiroideo medular.
RU2328504C2 (ru) 2001-03-08 2008-07-10 Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд Антагонисты соматостатина
US7312304B2 (en) 2001-04-09 2007-12-25 The Administrators Of The Tulane Educational Fund Somatostatin agonists

Also Published As

Publication number Publication date
NO20033911L (no) 2003-10-29
US20040181032A1 (en) 2004-09-16
EP1372688A2 (en) 2004-01-02
NO20033911D0 (no) 2003-09-04
US20080020970A1 (en) 2008-01-24
EP1372688B1 (en) 2008-05-07
JP2006342171A (ja) 2006-12-21
HUP0401535A2 (hu) 2004-12-28
WO2002072602A2 (en) 2002-09-19
RU2005117614A (ru) 2006-11-20
US20080171853A1 (en) 2008-07-17
EP1372688A4 (en) 2006-06-14
RU2003129807A (ru) 2005-03-20
ATE394114T1 (de) 2008-05-15
AU2002258465B2 (en) 2006-01-19
JP4204322B2 (ja) 2009-01-07
CZ20032281A3 (cs) 2004-01-14
JP2008255120A (ja) 2008-10-23
CZ299362B6 (cs) 2008-07-02
ES2306766T3 (es) 2008-11-16
RU2263678C2 (ru) 2005-11-10
US7408024B2 (en) 2008-08-05
DK1372688T3 (da) 2008-08-25
WO2002072602A3 (en) 2003-03-20
US7378488B2 (en) 2008-05-27
CA2439498A1 (en) 2002-09-19
DE60226419D1 (de) 2008-06-19
RU2328504C2 (ru) 2008-07-10
JP2004532824A (ja) 2004-10-28
AR035942A1 (es) 2004-07-28
HUP0401535A3 (en) 2009-07-28

Similar Documents

Publication Publication Date Title
IL165841A0 (en) Mchir antagonists
AU2002341834A1 (en) Antagonists
SI1671949T1 (sl) Substituirani pridinilamini
HU0101106D0 (en) Id alsorithm
IL158051A0 (en) Somatostatin agonists
HK1063791A1 (en) Nk1 antagonists
PL362643A1 (pl) Podstawione fluoroalkoksyfenylosulfonylomoczniki
PL362838A1 (pl) Antagoniści somatostatyny
PL368050A1 (pl) Podstawione 4-aminocykloheksanole
EP1359932A4 (en) TIP39 POLYPEPTIDES
CA97154S (en) Drill
CA97153S (en) Drill
IL153176A0 (en) New phenylpiperazines
GB0112342D0 (en) Polypeptides
PL364601A1 (pl) Podstawione związki benzoheterocykliczne zawierające azot
PL364090A1 (pl) Nowe benzyloaminopirymidyny
GB0125051D0 (en) GT speedlock
CA94144S (en) Drill
CA93112S (en) Drill
GB0009125D0 (en) Antagonists
GB0006860D0 (en) Antagonists
GB0120289D0 (en) V place
GB0127164D0 (en) Micro-pin interface
GB0118302D0 (en) Tiles
GB0104937D0 (en) Improved wells

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)